Rectal CancerNCT05674097
Blood Flow Path Reconstruction in Rectal Cancer
An observational study of Rectal Cancer and Surgery, run by Shandong First Medical University at 1 site in China.
Trial summary
A total of 89 patients with distal sigmoid and rectal cancer were referred for observation and underwent MS-CTA between June 2020 and March 2022. The distribution of the left colic artery (LCA) was classified, and the presence of the accessory middle colic artery (AMCA) was assessed. Read more about this study
- Who is it for?
- Ages 39 to 81 years
- Conditions the study is for
- Rectal Cancer, Surgery, Image
- How many people
- 89 participants
- Where
- 1 siteChina
- Study dates
- 8 Jun 2020to 31 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 39 to 81 years
- All sexes
- Adult, Older adult
Study population: Patients with distal sigmoid colon or rectal cancer and they were received routine laparoscopic surgery.
Who may be able to join
- Clinical diagnosis of distal sigmoid colon or rectal cancer
- cTNM stage confirmed as I-III on MRI or CT
- Undergoing laparoscopic anterior resection (LAR)
Who cannot join
- Arterial phase scanning initiated too early
- Unclear anatomic structure on imaging
- No postoperative enhanced CT
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Blood Flow Path Reconstruction in Rectal Cancer After High IMA Ligation Through Preoperative and Postoperative Comparison by Manual Subtraction CTA
A total of 89 patients with distal sigmoid and rectal cancer were referred for observation and underwent MS-CTA between June 2020 and March 2022. The distribution of the left colic artery (LCA) was classified, and the presence of the accessory middle colic artery (AMCA) was assessed. Blood flow paths were planned preoperatively based on the classification of LCA branches. High ligation was performed during standard radical surgery. Intraoperatively, particular care was taken to preserve the bifurcation of the ascending and descending branches of the LCA. The planned blood flow paths were then compared with the actual postoperative blood flow paths to validate the previously proposed mechanism.
- Conditions
- Rectal Cancer, Surgery, Image
- Being tested
- no intervention
- Medical subject headings
- Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
no interventionOther
no intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Six pattens of blood flow and AMCA based on the preoperative observation
Measured: 1 hour after the manual subtraction computed tomography angiography (MS-CTA) procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2023
- Study start8 Jun 2020
- Primary completion8 Mar 2022
- Study completion31 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 89 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shandong First Medical University
- Sponsor type
- University, hospital or other
- Collaborators
- Jinan Central Hospital
- Responsible party
- Principal investigator, Guoqin LIU, Shandong First Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05674097
- Sponsor's protocol ID
- 2020GQliu
- Status last verified
- Dec 2022
- First submitted
- 21 Dec 2022
- Last updated
- 22 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: It will be available when our paper is accepted.
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Blood Flow Path Reconstruction in Rectal Cancer After High IMA Ligation Through Preoperative and Postoperative Comparison by Manual Subtraction CTA
- ClinicalTrials.gov ID
- NCT05674097
- Acronym / sponsor ID
- 2020GQliu
- Conditions
- Rectal Cancer, Surgery, Image
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 89 participants (actual)
- Lead sponsor
- Shandong First Medical UniversityUniversity, hospital or other
- Collaborators
- Jinan Central Hospital
- Study start
- 8 Jun 2020 (actual)
- Primary completion
- 8 Mar 2022 (actual)
- Study completion
- 31 Mar 2022 (actual)
- First posted
- 6 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A total of 89 patients with distal sigmoid and rectal cancer were referred for observation and underwent MS-CTA between June 2020 and March 2022. The distribution of the left colic artery (LCA) was classified, and the presence of the accessory middle colic artery (AMCA) was assessed. Blood flow paths were planned preoperatively based on the classification of LCA branches. High ligation was performed during standard radical surgery. Intraoperatively, particular care was taken to preserve the bifurcation of the ascending and descending branches of the LCA. The planned blood flow paths were then compared with the actual postoperative blood flow paths to validate the previously proposed mechanism.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 39 to 81 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients with distal sigmoid colon or rectal cancer and they were received routine laparoscopic surgery.
Key inclusion criteria (3 listed)
- Clinical diagnosis of distal sigmoid colon or rectal cancer
- cTNM stage confirmed as I-III on MRI or CT
- Undergoing laparoscopic anterior resection (LAR)
Key exclusion criteria (3 listed)
- Arterial phase scanning initiated too early
- Unclear anatomic structure on imaging
- No postoperative enhanced CT
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| no interventionno intervention | Other | – |
Primary outcome
Six pattens of blood flow and AMCA based on the preoperative observation
Time frame: 1 hour after the manual subtraction computed tomography angiography (MS-CTA) procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2025.
- Individual participant dataSharing planned: No. It will be available when our paper is accepted.
Related trials for Rectal Cancer
RecruitingObservational study
ABCSG R07 Rectal Cancer Registry
Rectal Cancer, Adenocarcinoma of Rectum
Not yet recruitingPhase 2
Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer
Locally Advanced Resectable Rectal Cancer
Not yet recruitingPhase 2
Adaptive Radiotherapy for Safe Hypofractionation
Cancer, Endometrial Cancer
Not yet recruiting
Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer
Locally Advanced Rectal Cancer, Rectal Adenocarcinoma
Not yet recruitingPhase 2
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer
Colo-rectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Rectal Cancer and Surgery, run by Shandong First Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Six pattens of blood flow and AMCA based on the preoperative observation (time frame: 1 hour after the manual subtraction computed tomography angiography (MS-CTA) procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025; AzTrials last refreshed its copy on 1 Nov 2026.